8-K: Alkermes Reports Profitable First Quarter 2024, Driven by Neuroscience Focus

Alkermes announced a profitable first quarter of 2024 with $350.4 million in revenue, marking its first full quarter as a pure-play neuroscience company.

Summary

• Alkermes reported a profitable first quarter in 2024, with total revenues reaching $350.4 million, a 22% increase compared to $287.6 million in the same period last year.
• The company's GAAP net income from continuing operations was $38.9 million, or $0.23 per diluted share, a significant improvement from a loss of $12.1 million in the first quarter of 2023.
• Non-GAAP net income from continuing operations was $76.2 million, compared to $30.1 million in the prior year.
• EBITDA from continuing operations was $51.5 million, a substantial increase from $7.2 million in the first quarter of 2023.
• LYBALVI revenues grew by 50% to $57.0 million, with total prescriptions increasing by 56% year-over-year.
• VIVITROL revenues were $97.7 million, and ARISTADA revenues were $78.9 million.
• Manufacturing and royalty revenues totaled $116.8 million, including $62.7 million from INVEGA products and $31.3 million from VUMERITY.
• The company's cash, cash equivalents, and total investments stood at $807.8 million as of March 31, 2024.
• Alkermes reiterated its 2024 financial expectations, projecting total revenues between $1.5 billion and $1.6 billion, and GAAP net income between $350 million and $390 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the company's return to profitability, strong revenue growth, and advancement of its pipeline. The reiteration of positive financial guidance for 2024 further supports this positive outlook. However, there are some risks and challenges mentioned, which prevent a perfect score.

Positives

• The company achieved a significant turnaround to profitability in Q1 2024.
• LYBALVI demonstrated strong growth with a 50% increase in revenue and a 56% increase in prescriptions.
• The company is actively advancing its pipeline, particularly ALKS 2680, with ongoing and planned phase 2 studies.
• Alkermes has a strong cash position with $807.8 million in cash, cash equivalents, and total investments.
• The company reiterated its positive financial outlook for 2024.

Negatives

• ARISTADA revenues decreased slightly by 2% year-over-year to $78.9 million.
• The company experienced a decrease in inventory across its key products, including LYBALVI, ARISTADA, and VIVITROL.
• R&D expenses increased year-over-year due to investments in the ALKS 2680 program and non-recurring share-based compensation expenses.
• SG&A expenses also increased due to investments in the LYBALVI direct-to-consumer advertising campaign and non-recurring share-based compensation expenses.

Risks

• The company faces risks related to the commercialization of its products, including potential competition from generic manufacturers.
• Clinical development activities may not be completed on time or at all, and results may not be positive.
• Regulatory authorities may not agree with the company's approval strategies or may make adverse decisions regarding its products.
• There is a risk of reduction in payment rates or reimbursement for the company's products.
• The company's products may prove difficult to manufacture or have unintended side effects.

Future Outlook

Alkermes reiterated its 2024 financial expectations, projecting total revenues between $1.5 billion and $1.6 billion, GAAP net income between $350 million and $390 million, and EBITDA between $445 million and $485 million. The company also plans to advance its neuroscience pipeline, particularly the ALKS 2680 program, with further clinical development activities.

Management Comments

• Richard Pops, Chief Executive Officer of Alkermes, stated that the first quarter of 2024 marks the company's first full quarter as a profitable, pure-play neuroscience company.
• He highlighted the solid underlying prescription growth for LYBALVI and the advancement of ALKS 2680 as key achievements during the quarter.
• He also noted that orexin 2 biology represents an important new potential approach to treating disorders characterized by excessive daytime sleepiness.

Industry Context

This announcement reflects a positive shift for Alkermes as it focuses on its neuroscience portfolio after separating its oncology business. The company's progress with ALKS 2680 aligns with the growing interest in orexin-based therapies for sleep disorders. The strong performance of LYBALVI indicates a successful commercial strategy in the schizophrenia and bipolar I disorder market. The company's financial results and pipeline progress position it well within the competitive biopharmaceutical landscape.

Comparison to Industry Standards

• Alkermes' revenue growth of 22% year-over-year is a strong performance compared to many established pharmaceutical companies, although direct comparisons are difficult due to the company's specific product portfolio and focus on neuroscience.
• The 50% growth in LYBALVI revenue and 56% growth in prescriptions is particularly notable, indicating a successful launch and market penetration, which is a key metric for new pharmaceutical products.
• The company's transition to profitability is a significant achievement, as many biopharmaceutical companies, especially those focused on research and development, often operate at a loss for extended periods.
• The advancement of ALKS 2680 into phase 2 trials is in line with industry standards for drug development timelines, and the focus on orexin-based therapies is a growing trend in the treatment of sleep disorders, with companies like Jazz Pharmaceuticals also exploring this area.
• Alkermes' cash position of $807.8 million provides a solid financial foundation for continued research and development, which is crucial for biopharmaceutical companies.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the company's return to profitability and strong financial performance.
• Employees may benefit from the company's growth and success.
• Patients may benefit from the development of new treatments for neurological disorders.
• Customers will continue to have access to Alkermes' commercial products.
• Suppliers and creditors will likely view the company's financial stability favorably.

Next Steps

• Alkermes plans to present additional phase 1b data for ALKS 2680 at SLEEP 2024 in June.
• The company will continue to enroll patients in the Vibrance-1 phase 2 study for ALKS 2680 in narcolepsy type 1.
• Alkermes plans to initiate a phase 2 study (Vibrance-2) for ALKS 2680 in narcolepsy type 2 in the second half of 2024.
• The company will continue to advance its internal development candidates and explore external pipeline opportunities.
• Alkermes will continue to focus on capital allocation, including potential opportunities to return capital to shareholders.

Key Dates

Keywords

Alkermes, Neuroscience, LYBALVI, VIVITROL, ARISTADA, ALKS 2680, Narcolepsy, Orexin 2 Receptor Agonist, Financial Results, Profitability, Biopharmaceutical